A recent research letter highlighted a case observed in Japan in which a patient with alopecia totalis, and an associated case of atopic dermatitis, was treated effectively with baricitinib, a JAK inhibitor.
Tim Smith
Advertisement
Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.
Articles by Tim Smith
Recent phase 3 trial data suggests the efficacy across multiple endpoints of roflumilast foam as a treatment for seborrheic dermatitis.
New research suggests the sleep quality of caregivers and patients with atopic dermatitis (inadequately-controlled with topical therapies) may improve with dupilumab treatment.
Recent clinical trial data from UNCOVER-1 and UNCOVER-2 demonstrated the positive effects of ixekizumab use in adult plaque psoriasis patients.
During a recent interview regarding ReOpen1 and ReOpen2 trials, Dr. Mahmoud described a new treatment device for chronic rhinosinusitis patients.
The recent GUIDE study examined the efficacy of guselkumab for moderate-to-severe plaque psoriasis, finding it consistent with previous trials.
Recent phase 3 trial results suggest positive effects and faster onset using CAL/BDP cream for adult plaque psoriasis.
A discussion regarding the use of plaque psoriasis treatments such as apremilast, ixekizumab, and methotrexate.
When compared to an intervention system guided by a therapist, a newly-designed self care system for atopic dermatitis patients may be as helpful.
Dr. Chopra elaborated on his Pri-Med Midwest 2022 presentation regarding the future of advances in medicine, specifically highlighting artificial intelligence, gut microbiome research, and gene editing.
Dr. Chopra described several key points of his Pri-Med Midwest presentation regarding the future of advances in medicine, including artificial intelligence, gut bacteria, and CRISPR technology.
A highlighted description of some key takeaways from presentations at Pri-Med Midwest 2022, including such topics as infectious disease, monkeypox, colorectal cancer, psoriasis, and COVID-19.
An interview with Dr. Anwuri regarding her Pri-Med Midwest presentation on treating adult plaque psoriasis.
In an interview during Pri-Med Midwest, Dr. Kushner spoke about the benefits of treating obesity and diabetes synchronously.
A discussion with Dr. Vega regarding colorectal cancer screenings, aspirin use recommendations, and the current state of healthcare.
Charles Vega, MD: Atrial Fibrillation, Risk Factors for Autosomal Dominant Polycystic Kidney Disease
An interview with Dr. Vega regarding atrial fibrillation and clinical manifestations for ADPKD.
A discussion with Dr. Angarone regarding his presentation at Pri-Med Midwest, exploring the topic of treating infectious disease in developing countries.
A discussion regarding highlights from Dr. Charles Vega’s presentation on common urgent care presentations and concerns regarding acute pain.
Dr. Angarone highlighted several key takeaways from his presentation at Pri-Med Midwest.
A discussion regarding highlights from Dr. Michael Angarone’s presentation on emerging infectious diseases.
Research suggests disparities between racial and ethnic groups exist among patients with Alzheimer’s disease and related dementias.
A recent study confirmed the safety of tralokinumab with regard to COVID-19 and related vaccinations.
Researchers evaluated the use of IVIG for patients with the rare autoimmune disorder dermatomyositis.
A recent cohort study of 20 emergency departments assessed allergic contact dermatitis cases.
Children at risk for developing asthma may see benefits from a new screening tool developed to detect symptoms in children age 3 and up.
A research team described data regarding the potential of escalating adalimumab doses for certain patients with psoriasis.
A recent study found that worsened visual acuity and depression were associated with neurobiological changes visible through MRI scans.
A combination therapy approach may be useful for psoriasis treatment, though an 8-week regimen may not be long enough.
A discussion with Dr. Lal on the successful trials and recent approval of dupilumab as a treatment for skin inflammation.
Data indicates a greater number of physicians is a better predictor of melanoma diagnoses than UV radiation rates.
Advertisement
Advertisement
Advertisement
Trending on HCPLive
1
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
2
Cannabis Use Tied to Higher Odds of Stroke, Cardiovascular Disease
3
ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD
4
AHA 2026: Intensive Blood Pressure Control Reduces Events After Ischemic Stroke
5